PATENT CLAIM ANALYSIS

Application Number: 15982449
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "220000"]

Abstract:
The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.

Claim (Index 1):
A method of treating schizophrenia or bipolar disorder in a patient comprising:\n subcutaneously administering to the patient, with a frequency of no more than once per 21 days, a sustained-release pharmaceutical dosage form comprising olanzapine, or a pharmaceutically acceptable salt thereof; wherein the dosage form provides a therapeutically effective dose of olanzapine for a period of at least 21 days; and wherein said method is performed without monitoring for post-injection delirium/sedation syndrome (PDSS).

Metadata:
- Claim Count in Document: 29.0
- Percentile: 93.0
- Lexical Diversity: 1.53333
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15926076', '11274887', '14773642', '15101874', '14995658']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7450809052746018
- 35 USC 102 Novelty (BERT): 0.5848409561654437
- Combined Prediction Score: 0.7290569103636859
- Mean Citation Score: 251.3072200000001
- Max Citation Score: 481.5187
- Similarity Product: 439.0947422129869

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test